Title DISEASE CONTROL RATE AT 8 WEEKS PREDICTS SUBSEQUENT SURVIVAL IN PLATINUM-TREATED EXTENSIVE STAGE SMALL CELL LUNG CANCER ( ES-SCLC ) : A PATIENT LEVEL ANALYSIS OF SWOG TRIALS Permalink

J. Moon,M. Redman,T. Semrad,K. Kelly,J. Allen,B. Gitlitz,P. Mack,D. Gandara

Published 2015 in Unknown venue

ABSTRACT

No abstract is available for this paper.

PUBLICATION RECORD

Publication year
2015
Venue
Unknown venue
Publication date
Unknown publication date
Fields of study
Not labeled
Identifiers
No identifiers available.
External record
Open on Semantic Scholar
Source metadata
Semantic Scholar

CITATION MAP

EXTRACTION MAP

CLAIMS

No claims are published for this paper.

CONCEPTS

No concepts are published for this paper.

REFERENCES

Reply to "diminishing role of platinum-sensitivity status in patients with small cell lung cancer".
2015cited by this paper
Relevance of Platinum-Sensitivity Status in Relapsed/Refractory Extensive-Stage Small-Cell Lung Cancer in the Modern Era: A Patient-Level Analysis of Southwest Oncology Group Trials
2015cited by this paper
Multitrial evaluation of progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in previously untreated extensive-stage small cell lung cancer (ES-SCLC): An Alliance-led analysis.
2013cited by this paper
Tumor response and progression‐free survival as potential surrogate endpoints for overall survival in extensive stage small‐cell lung cancer
2011cited by this paper
Sorafenib in Platinum-Treated Patients with Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group (SWOG 0435) Phase II Trial
2010cited by this paper
Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials.
2008cited by this paper
Management of recurrent small cell lung cancer.
2008cited by this paper
Bortezomib (PS-341) in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group Phase II Trial (S0327)
2006cited by this paper
Surrogate endpoints in clinical trials: definition and operational criteria.
1989influential reference

CITED BY

No citing papers are available for this paper.